Evan C Chen
Overview
Explore the profile of Evan C Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen E, Shimony S, Luskin M, Stone R
Am J Hematol
. 2025 Feb;
100(4):652-665.
PMID: 39901865
Mutations in nucleophosmin 1 (NPM1) are diseased-defining genetic alterations encountered in approximately one-third of cases of acute myeloid leukemia (AML). A mutation in NPM1 confers a more favorable prognosis; however,...
2.
Gui G, Ravindra N, Hegde P, Andrew G, Mukherjee D, Wong Z, et al.
Bone Marrow Transplant
. 2024 Nov;
60(2):154-160.
PMID: 39506075
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD...
3.
Gui G, Ravindra N, Hegde P, Andrew G, Mukherjee D, Wong Z, et al.
Bone Marrow Transplant
. 2024 Oct;
60(2):144-153.
PMID: 39455897
Routine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for...
4.
Roloff G, Aldoss I, Kopmar N, Lin C, Dekker S, Gupta V, et al.
J Clin Oncol
. 2024 Oct;
43(5):558-566.
PMID: 39418622
Purpose: On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October...
5.
Poston J, Bryan C, von Drygalski A, Al Banaa K, Zhou J, Parnes A, et al.
Blood Adv
. 2024 Oct;
8(22):5896-5905.
PMID: 39361769
Acquired hemophilia A (AHA) is an autoimmune bleeding disorder that is caused by factor VIII (FVIII) autoantibodies with high morbidity and mortality due to bleeding and complications from immunosuppression (IST)....
6.
Chen E, Flamand Y, Tiao E, DeAngelo D, Luskin M
Leuk Lymphoma
. 2024 Sep;
66(1):64-71.
PMID: 39282955
Blinatumomab is a CD3 × CD19 antibody approved for adults with B-cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is not considered myelosuppressive, but significant neutropenia has been seen in practice. We...
7.
Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, et al.
Blood Adv
. 2024 Jun;
8(18):4845-4855.
PMID: 38941537
Although intensive induction chemotherapy (IC) remains the standard of care for younger patients with acute myeloid leukemia (AML), hypomethylating agents + venetoclax (HMA/VEN) can lead to durable remission among older...
8.
Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, et al.
Am J Hematol
. 2024 May;
99(8):1640-1643.
PMID: 38751104
No abstract available.
9.
Patel A, Yoon J, Johnston H, Davidson M, Shallis R, Chen E, et al.
Blood Adv
. 2024 May;
8(13):3468-3477.
PMID: 38739724
Progression of myeloproliferative neoplasms (MPNs) to accelerated or blast phase is associated with poor survival outcomes. Since 2017 there have been several therapies approved for use in acute myeloid leukemia...
10.
Shimony S, Garcia J, Keating J, Chen E, Luskin M, Stahl M, et al.
Leukemia
. 2024 Mar;
38(7):1494-1500.
PMID: 38538860
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML patients, we evaluated...